期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 51, 期 3, 页码 694-702出版社
WILEY
DOI: 10.1002/eji.202048857
关键词
Biological therapy; Cardiovascular risk; Mass cytometry; PD-1; Psoriasis; Systemic inflammation
类别
资金
- Faculty of Medicine, University of Bergen, Norway
- Department of Clinical Science, University of Bergen, Norway
- Broegelmann Foundation
- Norwegian Research Council
- Western Norway Regional Health Authorities
This study analyzed peripheral blood mononuclear cells (PBMCs) in psoriasis patients and healthy controls, finding an increase in certain immune cells in severe psoriasis patients, and relief of systemic inflammation after biological treatment.
Psoriasis is a chronic immune-mediated skin disease accompanied by systemic inflammation and comorbidities. We analyzed peripheral blood mononuclear cells (PBMCs) in the search for immune signatures and biomarkers related to psoriasis severity and treatment effect. Thirty-two patients with psoriasis and 10 matched healthy controls were included. PBMCs were collected before and after initiation of anti-TNF, anti-IL-17 or anti-IL-12/23 treatment and analyzed utilizing 26-parameter mass cytometry. The number of circulating Th17, Th22, Th9, and cytotoxic T cells were increased in severe psoriasis. Intracellular pp38 and pERK in T helper cells were associated with disease severity. Differences between responders and nonresponders regarding cell composition and intracellular signaling were identifiable already at inclusion. Biological treatment induced memory cells, restored inhibitory PD-1 function of T cells, and reduced a potential pro-atherogenic profile in monocytes. In conclusion, these results indicate amelioration of systemic inflammation in psoriasis after biological treatment. Such broad immune profiling may enable prospective stratification of patients regarding future treatment response. Successful early intervention may lead to a healthier trajectory with favorable implications on later comorbidities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据